Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
51 stopped studies mapped to Erythroid Neoplasm and descendants · 76% state a reason
Over the 51 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05853458 | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM…(HU-F-AIM) | Phase 4 | terminated | May 10, 2023 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT06290765 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera(PV) | Phase 4 | withdrawn | Mar 4, 2024 | PharmaEssentia | In alignment with company strategic direction. | Sponsor / business decision |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 18, 2019 | Ohio State University Comprehensive Cancer Center | The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice… | Enrollment / accrual |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic… | Phase 2 | terminated | Sep 10, 2019 | Fred Hutchinson Cancer Center | The federal funding period ended. The study was originally intended to be multi-site but was only… | Enrollment / accrual |
| NCT03755518 | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary…(FREEDOM) | Phase 3 | terminated | Nov 28, 2018 | Celgene | Slow accrual. | Enrollment / accrual |
| NCT03972943 | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential… | Early Phase 1 | terminated | Jun 4, 2019 | University of Utah | Study terminated due to lack of funding | Funding |
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera… | Phase 1 | withdrawn | May 21, 2021 | Lynk Pharmaceuticals Co., Ltd | sponsor decision | Sponsor / business decision |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT01014546 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | Phase 1 | terminated | Nov 17, 2009 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2012 | Roswell Park Cancer Institute | Sponsor wanted study rewritten | Other (stated, no rule matched) |
| NCT03287245 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of… | Phase 2 | terminated | Sep 19, 2017 | Hoffmann-La Roche | The Sponsor decided to discontinue the development of idasanutlin in the polycythemia vera… | Sponsor / business decision |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and…(PAC326) | Phase 3 | terminated | Feb 5, 2014 | CTI BioPharma | not stated | Not stated |
| NCT02105116 | AML Therapy With Irradiated Allogeneic Cells | N/A | terminated | Apr 7, 2014 | Rutgers, The State University of New Jersey | No patients were eligible to receive the experimental component of the protocol therapy. | Other (stated, no rule matched) |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | Phase 1 | withdrawn | Feb 25, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | Phase 3 | terminated | Jan 23, 2013 | CTI BioPharma | not stated | Not stated |
| NCT01038856 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera(OSI-TAR-766) | Phase 2 | terminated | Dec 24, 2009 | University of Oklahoma | The study was terminated by the sponsor | Other (stated, no rule matched) |
| NCT03121599 | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | N/A | terminated | Apr 20, 2017 | Hamad Medical Corporation | Delayed study materials, poor recruitment | Enrollment / accrual |
| NCT01998828 | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential… | Phase 2 | terminated | Dec 2, 2013 | Sierra Oncology LLC - a GSK company | not stated | Not stated |
| NCT02871323 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential… | Phase 1 | withdrawn | Aug 18, 2016 | Northwestern University | PI decided to withdraw the study after it opened for enrollment but before any patients were… | Enrollment / accrual |
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera… | Phase 2 | withdrawn | Aug 13, 2019 | M.D. Anderson Cancer Center | "Company is in a process of being taken over by another pharma and the new one has different ideas… | Sponsor / business decision |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jan 8, 2014 | Steven E. Coutre | Regulatory | Other (stated, no rule matched) |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Phase 1 | terminated | May 8, 2013 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT01904643 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or… | Phase 1 | terminated | Jul 22, 2013 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | withdrawn | Apr 18, 2013 | Stanford University | not stated | Not stated |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | Phase 1 | terminated | Feb 28, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT02049801 | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or… | Phase 1 | terminated | Jan 30, 2014 | Bruno C. Medeiros | logistics | Other (stated, no rule matched) |
| NCT00101140 | Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | Phase 2 | withdrawn | Jan 10, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating… | Phase 1 / Phase 2 | terminated | Apr 27, 2011 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00538980 | Dasatinib in Polycythemia Vera | Phase 2 | terminated | Oct 3, 2007 | Weill Medical College of Cornell University | This study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated… | Phase 2 | terminated | May 7, 2008 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | Phase 2 | terminated | Nov 4, 2011 | Fred Hutchinson Cancer Center | Closed early due to slow enrollment | Enrollment / accrual |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or… | Phase 2 | terminated | May 30, 2012 | Fred Hutchinson Cancer Center | The study was terminated early because there were other competing protocols. | Other (stated, no rule matched) |
| NCT02805868 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential… | Early Phase 1 | withdrawn | Jun 20, 2016 | Northwestern University | Funding | Funding |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With… | Phase 2 | terminated | Jan 7, 2014 | Roswell Park Cancer Institute | Major revisions needed in study | Other (stated, no rule matched) |
| NCT02663648 | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | — | withdrawn | Jan 26, 2016 | Shandong University | No eligible patient was enrolled. | Enrollment / accrual |
| NCT00595829 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera | Phase 1 | terminated | Jan 16, 2008 | Exelixis | not stated | Not stated |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With… | Phase 1 | terminated | Dec 15, 2010 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive… | Phase 2 | terminated | Jan 31, 2012 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT01291784 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | Phase 1 | terminated | Feb 8, 2011 | John Mascarenhas | Early termination when the drug was no longer made available by the pharmaceutical company due to… | Sponsor / business decision |
| NCT00940784 | Clopidogrel and Aspirin for the Treatment of Polycythemia Vera(ISCLAP) | Phase 2 | withdrawn | Jul 16, 2009 | Ronald Hoffman | Could not get drug | Other (stated, no rule matched) |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Jul 9, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00089388 | Cilengitide in Treating Patients With Acute Myeloid Leukemia | Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00096148 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly… | Phase 2 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01645124 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)(CYTO-PV) | Phase 3 | terminated | Jul 20, 2012 | Consorzio Mario Negri Sud | Low accrual rate not allowing planned sample size leads to a futility condition | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials